A 52-week, randomized, open-label, parallel-group, phase 3a trial with real-world elements was conducted at 176 sites in seven countries. A total of 1085 insulin-naive patients with type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results